摘要
目的:观察舒洛地特对2型糖尿病早期肾病的治疗作用。方法:144例不伴高血压的2型糖尿病早期肾病患者,代谢控制稳定后,原糖尿病治疗方案不变,随机分为常规治疗组、舒洛地特治疗组、苯那普利治疗组及舒洛地特+苯那普利治疗组。观察治疗前、治疗4周、治疗12周,尿白蛋白/尿肌酐(ACR)的变化,同时观察空腹血糖、糖化血红蛋白、血总胆固醇、血甘油三酯、血肌酐、纤维蛋白原的变化。结果:除常规治疗组外,其他三组治疗12周前后的ACR比较均有统计学差异(P<0.01)。治疗12周后,舒洛地特治疗组、苯那普利治疗组、舒洛地特+苯那普利治疗组与常规治疗12周后相比,ACR下降有统计学差异(P<0.01),但3组间治疗后12周的差异无统计学意义(P>0.05)。结论:舒洛地特能减少2型糖尿病早期肾病的ACR,延缓肾病的进展,是一种新的治疗糖尿病肾病的途径。
Objective： To observe the treatment effect of sulodexide in treatment of type 2 diabetes with early nephropathy. Methods： After metabolic control was stabilized, original treatment plan was maintained, 144 patients with type 2 diabetes with early nephropathy were divided randomly into four groups： routine group, sulodexide group, benazepril group and sulodexide＋ benazepril group. Compared the index changes after four weeks and 12 weeks,the test index included urine albumin/unrine creatinine（ ACR）, fasting blood glucose, glycosylated hemoglobin, total eholestrol, triglyceride,serum creatinine,fibrinogen. Results： ACR change of routine group after 12 weeks treatment was not obvious. ACR changes of other three groups were obvious excluding routine group（P〈0.01）. There were obvious difference between ACR of sulodexide group,benazepril group, sulodexide＋ benazepril group and that of routine group after 12 weeks treatment,statistic analysis showed no difference between these three groups （P〉0.05）. Conclusions： Sulodexide can reduce ACR of type 2 diabetes with early nephropathy, postponed the progression of diabetes nephropathy, sulodexide is a ＇new method of diabetes nephropathy treatment.
出处
《医药世界》
2009年第12期769-771,共3页
Medicine World
